ACT Capital Management’s Palvella Therapeutics PVLA Stock Holding History

ACT Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.44M	Buy	+22,500	New	+$2.73M	2.25%	13

Other funds holding PVLA

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

CAM

Clio Asset Management Charlottesville, Virginia $126M AUM 16.01% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

KOCAA

Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return

Aspiriant LLC Los Angeles, California $4.05B AUM 19.01% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

ACT Capital Management's PVLA Position: Q2 2026 in Review

ACT Capital Management opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 22,500 shares worth $3.44M. The stake represents 2.25% of the portfolio and ranks #13 among its holdings.

32 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

ACT Capital Management held 22,500 shares of Palvella Therapeutics worth $3.44M as of Q2 2026.
Palvella Therapeutics was a new ACT Capital Management position in Q2 2026.
Palvella Therapeutics made up 2.25% of ACT Capital Management's portfolio in Q2 2026, its #13 holding.
32 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.